Abstract:Tralokinumab was approved in December 2021 in the USA for the treatment of moderate-to-severe atopic dermatitis (AD) in adults. Real-world characteristics of patients prescribed tralokinumab are not yet understood. This study aims to characterize the demographic, medical history and clinical baseline characteristics of patients prescribed tralokinumab in US dermatology practices and integrated delivery networks. A retrospective analysis of adult patients prescribed tralokinumab between February and October 202… Show more
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.